
Opinion|Videos|March 27, 2025
Monitoring Strategies for Managing ADC Toxicities in mBC
Panelists discuss how pharmacists should monitor neutropenia, diarrhea, and mucositis from sacituzumab govitecan (SG); interstitial lung disease (ILD) and neutropenia from trastuzumab deruxtecan (T-DXd); and neutropenia and ILD from datopotamab deruxtecan (Dato-DXd). Proactive management is essential for patient safety.
Advertisement
Video content above has been prompted by the following:
- Toxicity management is critical for patients on antibody-drug conjugates (ADCs). What are the most important ADC-related AEs that pharmacists should monitor (eg, neutropenia, diarrhea, ILD, mucositis) for T-DXd, SG, and Dato-DXd?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
Rapid CAR T Expansion Linked to Delayed Neurotoxicity in Patients Treated With Cilta-Cel
2
Hercessi, Biosimilar to Herceptin, Shows Favorable Efficacy, Safety in Treating HER2+ MBC in Real-World Setting
3
IMS: Shaping the Future of Multiple Myeloma with Anti-CD38 Quadruplets
4
Nirmatrelvir-Ritonavir Has Variable Impact on Incidence of Post-COVID-19 Condition
5